Project archive

The purpose of SMA Europe is to provide a framework to stimulate collaboration

and accelerate translational research pathways in SMA and promote patient care.

New drugs and new drug targets for Spinal Muscular Atrophy using chemical and functional genomics

Principal investigator(s):
Professor David Sattelle
Institution:
University of Manchester, UK
Grant:
74,575€
Grant Type:
Operating Grant
Call number:
3
Start year:
2011
Duration:
1 year

AAV9-mediated gene therapy in murine and feline models of SMA

Principal investigator(s):
Dr. Martine Barkats
Institution:
INSERM, Paris, France
Grant:
164,725€
Grant Type:
Operating Grant
Call number:
3
Start year:
2011
Status:
Not yet started

Evaluation of the contribution of SMN1 and SMN2 sequence variants to the clinical severity of SMADr. Kathleen Mahias

Principal investigator(s):
Dr. Kathleen Mahias
Institution:
INSERM, Rouen, France
Grant:
€27,250
Call number:
4
Start year:
2012
Duration:
1 year
Status:
Ended

AAV9- mediated gene therapy in murine models of SMA

Principal investigator(s):
Dr. Yannick Tanguy
Institution:
INSERM, Paris, France
Grant:
97,068€
Grant Type:
Fellowship
Call number:
4
Start year:
2012
Duration:
2 years

Spinal Muscular Atrophy: Molecular and functional analysis of a new modifier of SMA

Principal investigator(s):
Dr. Markus Riessland
Institution:
University of Cologne, Germany
Grant:
€124,000
Call number:
4
Start year:
2012
Duration:
2 years
Status:
Ended